Evaluation of β-cell secretory capacity using glucagon-like peptide 1

被引:38
作者
Vilsboll, T
Toft-Nielsen, MB
Krarup, T
Madsbad, S
Dinesen, B
Holst, JJ
机构
[1] Univ Copenhagen, Gentofte Hosp, Dept Internal Med F, DK-2900 Hellerup, Denmark
[2] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark
[4] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
D O I
10.2337/diacare.23.6.807
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - beta-Cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is preserved in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - We first compared the effects of intravenous bolus injections of 2.5, 5, 15, and 25 nmol GLP-1 with glucagon (1 mg intravenous) and a standard meal (566 kcal) in 6 type 2 diabetic patients and 6 matched control subjects. Next, we studied another 6 patients and 6 control subjects and, in addition to the above procedure, performed a combined glucose plus GLP-1 stimulation, where plasma glucose was increased to 15 mmol/l before injection of 2.5 nmol GLP-1. Finally, we compared the insulin response to glucose plus GLP-1 stimulation with that observed during a hyperglycemic arginine clamp (30 mmol/l) in 8 patients and 8 control subjects. RESULTS - Peak insulin and C-peptide concentrations were similar after the meal, after 2.5 nmol GLP-1, and after glucagon. Side effects were less with GLP-1 than with glucagon. Peak insulin and C-peptide concentrations were as follows (C-peptide concentrations are given in parentheses): for patients (n = 12): meal, 277 +/- 42 pmol/l (2,181 +/- 261 pmol/l); GLP-1 (2.5 nmol), 390 +/- 74 pmol/l (2,144 +/- 254 pmol/l); glucagon, 329 +/- 50 pmol/l (1,780 +/- 160 pmol/l); glucose plus GLP-1, 465 +/- 87 pmol/l (2,384 +/- 2,99 pmol/l); for control subjects (n = 12). meal, 543 +/- 89 pmol/l (2,873 +/- 210 pmol/l); GLP-1, 356 +/- 51 pmol/l (2,001 +/- 130 pmol/l); glucagon, 420 +/- 61 pmol/l (1,995 +/- 99 pmol/l); glucose plus GLP-1, 1,412 +/- 187 pmol/l (4,391 +/- 416 pmol/l). Peak insulin and C-peptide concentrations during the hyperglycemic arginine damp and during glucose plus GLP-1 injection were as follows. for patients. 475 +/- 141 pmol/l (2.295 +/- 379 pmol/l) and 816 +/- 268 pmol/l (3,043 +/- 508 pmol/l), respectively; for control subjects: 1,403 +/- 308 pmol/l (4,053 +/- 533 pmol/l) and 2,384 +/- 452 pmol/l (6,047 +/- 692 pmol/l), respectively. CONCLUSIONS- GLP-1 (2.5 nmol = 9 mu g) elicits similar secretory responses to 1 mg glucagon (but has fewer side effects) and a standard meal. Additional elevation of plasma glucose to 15 mmol/l did not enhance the response further. The incremental response was similar to that elicited by arginine, but hyperglycemia had an additional effect on the response to arginine.
引用
收藏
页码:807 / 812
页数:6
相关论文
共 20 条
[1]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[2]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[3]   CHARACTERIZATION OF 7 C-PEPTIDE ANTISERA [J].
FABER, OK ;
BINDER, C ;
MARKUSSEN, J ;
HEDING, LG ;
NAITHANI, VK ;
KUZUYA, H ;
BLIX, P ;
HORWITZ, DL ;
RUBENSTEIN, AH .
DIABETES, 1978, 27 :170-177
[4]   CELL AND MOLECULAR-BIOLOGY OF THE INCRETIN HORMONES GLUCAGON-LIKE PEPTIDE-I AND GLUCOSE-DEPENDENT INSULIN RELEASING POLYPEPTIDE [J].
FEHMANN, HC ;
GOKE, R ;
GOKE, B .
ENDOCRINE REVIEWS, 1995, 16 (03) :390-410
[5]  
FRIER BM, 1977, DIABETES, V26, P369
[6]   Potential therapeutic level of glucagon-like peptide I achieved in humans by a buccal tablet [J].
Gutniak, MK ;
Larsson, H ;
Heiber, SJ ;
Juneskans, OT ;
Holst, JJ ;
Ahren, B .
DIABETES CARE, 1996, 19 (08) :843-848
[7]   POTENTIATION OF INSULIN SECRETORY RESPONSES BY PLASMA-GLUCOSE LEVELS IN MAN - EVIDENCE THAT HYPERGLYCEMIA IN DIABETES COMPENSATES FOR IMPAIRED GLUCOSE POTENTIATION [J].
HALTER, JB ;
GRAF, RJ ;
PORTE, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 48 (06) :946-954
[8]  
HARRIS M, 1979, DIABETES, V28, P1039
[9]   RADIOIMMUNOLOGICAL DETERMINATION OF HUMAN C-PEPTIDE IN SERUM [J].
HEDING, LG .
DIABETOLOGIA, 1975, 11 (06) :541-548
[10]   SIMILAR REDUCTION OF 1ST-PHASE AND 2ND-PHASE B-CELL RESPONSES AT 3 DIFFERENT GLUCOSE-LEVELS IN TYPE-II DIABETES AND THE EFFECT OF GLICLAZIDE THERAPY [J].
HOSKER, JP ;
RUDENSKI, AS ;
BURNETT, MA ;
MATTHEWS, DR ;
TURNER, RC .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (08) :767-772